Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Smoking Cessation, Alcohol Drinking
Interventions: Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring; Other · Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Necrotizing Pancreatitis
Interventions: Using ABTHERA Advance without a Wittmann Patch; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Osteoarthritis, Hip, Femoroacetabular Impingement, Osteonecrosis, Legg-Calvé-Perthes Disease, Osteochondral Lesion, Hip Dysplasia
Interventions: ReNew Hip Implant; Device
Lead sponsor: Cytex Therapeutics, Inc.; Other
Eligibility: 14 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myofascial Pain Syndromes
Interventions: Heated lidocaine/tetracaine patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chondrosis, Patellar Articular Cartilage Lesions, Trochlear Articular Cartilage Lesions
Interventions: Not listed
Lead sponsor: Orthopaedic Research Foundation; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2005
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder, Schizo Affective Disorder
Interventions: ABILIFY MYCITE; Combination Product
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more

Conditions: Evaluate the Use of a New Mesh Type in Open Inguinal Hernia Repair
Interventions: Open inguinal hernia repair with mesh; Procedure
Lead sponsor: Owen Drive Surgical Clinic of Fayetteville; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Fayetteville, North Carolina

Conditions: Ovarian Failure, Premature
Interventions: 17beta Estradiol, Conjugated estrogens, 17Beta Estradiol - transdermal, Progesterone, micronized; Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
Interventions: Sapphire 3 Coronary Dilatation Catheter; Device
Lead sponsor: OrbusNeich; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Stanford, California • Torrance, California • Atlanta, Georgia + 5 more

Conditions: RFA, Microwave Ablation, Pancreatic Lesion, Gastrointestinal Lesions, Ablation Techniques
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Coronary Artery Disease
Interventions: ABT NG DES 48 EECSS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more

Conditions: Locally Advanced Basal Cell Carcinoma
Interventions: L19IL2, L19TNF, L19IL2/L19TNF; Drug
Lead sponsor: Philogen S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Tampa, Florida • Atlanta, Georgia • Durham, North Carolina + 3 more

Conditions: Renal Cell Carcinoma
Interventions: CTT1057; Drug
Lead sponsor: Cancer Targeted Technology; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: HP828-101; Device
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Irving, Texas

Conditions: HIV Prevention
Interventions: Digital Health Feedback System; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: San Diego, California

Conditions: Erdheim-Chester Disease
Interventions: Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2, High Grade Cervical Intraepithelial Neoplasia
Interventions: Imiquimod, Topical Fluorouracil; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Coronary Artery Disease
Interventions: FFRangio; Device
Lead sponsor: CathWorks Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Roslyn, New York + 1 more

Conditions: Renal Artery Obstruction, Hypertension, Renal
Interventions: Herculink Elite Renal Stent System; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Atopic Dermatitis
Interventions: Locoid Lipocream, Hylatopic Plus; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 3 Months and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Erythema
Interventions: MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Migraine Disorders
Interventions: Sumatriptan succinate, NP101 Study Patch; Drug
Lead sponsor: NuPathe Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Hallandale, Florida

Conditions: Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 30 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 59 more

Search by objective public record fields.

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

ABTHERA ADVANCE™ Use Without Wittman Patch

Early Feasibility Study of Cartilage Defect Repair

Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points

Autologous Chondrocyte Implantation in the Patellofemoral Joint

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Use of Parietex Plug and Patch Hernia System in Open Inguinal Hernia Repair

Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure

Sapphire 3 CTO Study

EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry

Abbott Next Generation Drug Eluting Stent 48mm Study

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Cumulative Irritation Potential of 828 Ointment

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

FFRangio Accuracy vs. Standard FFR

The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch